DC －CIK 过继性细胞免疫治疗对卵巢癌患者的预后及免疫功能的影响

摘要

Objective:To investigate whether autologous dendritic cell(DC)-cytokine -induced killer(CIK)cell therapy is able to evaluate the therapeutic effect and safety in epithelial ovarian cancer.Methods:This study retro-spectively analyzed the clinical data from 90 cases selected from Chinese Medical University Shengjing Hospital during January 2014 to December 2015.The immune function,therapeutic effect and toxicity were compared between these groups after the treatment.Results:There were obvious changes of T cell subsets in the peripheral blood in the DC -CIK group(P <0.05),while the ratios of CD3 +,CD4 +,CD3 +,CD8 +,CD4 /CD8 +and CD16 +,CD56 +cells were significantly increased after the dendritic cells/cytokine induced killer cells adoptive immunotherapy treatment,and obviously increasing along with more courses(P <0.05).The progression -free survival of the simple observation group was shorter than that of the dendritic cells/cytokine induced killer cells adoptive immunotherapy group(15.88 ±2.7 months vs 22.5 ±4.13 months,P =0.039),while the progression -free survival had no significant difference with courses(P =0.412).Other side effects showed no significant differences between these groups,which can be al-leviated after symptomatic treatment.Conclusion:The DC -CIK immunotherapy was superior in prolonging the sur-vival time and enhancing immunological responses,and no obvious adverse reaction.%目的：探讨自体 DC －CIK 细胞疗法改善卵巢癌患者的预后及免疫功能的能力。方法：回顾性分析2014年1月至2015年12月在中国医科大学附属盛京医院均接受了规范的初始治疗、达到完全缓解（CR）的卵巢癌患者90例。分析比较其基本条件、免疫指标、无瘤生存时间及不良反应。结果：经 DC －CIK 生物免疫治疗的患者外周血 CD3＋、CD4＋细胞百分率，CD3＋、CD8＋细胞百分率及 CD4＋／CD8＋比值均上升，NK 细胞即CD16＋、CD56＋细胞增多，同时随着疗程数的增多，升高的更加明显（P ＜0．05）。一线治疗后，单纯观察组平均无瘤生存时间为15．88±2．7个月明显少于 DC －CIK 生物免疫治疗组的22．5±4．13个月（P ＝0．039）。其中使用 DC －CIK 生物免疫治疗疗程≥5程的平均无瘤生存时间为27．25±4．53个月明显高于 DC －CIK 生物免疫治疗疗程≤4程的19．69±2．81个月，两者相比差异无明显统计学意义（P ＝0．412）。所有患者 DC －CIK细胞治疗后血常规及肝肾功能检测与治疗前及单纯观察组患者相比无明显变化，也未见明显不良反应。结论：DC －CIK 免疫治疗提高卵巢癌患者的免疫反应，改善卵巢癌患者预后，未见明显不良反应。